Comment from Jitendra Pund

Dear Sir/Madam, Please find here with my comments on Investigating Out of Specification (OOS) Test Results for Pharmaceutical Production Guidance for Industry, Risk assessment must begin at the initiation of the OOS log, where a preliminary evaluation is performed to immediately safeguard patient safety, hold the affected batch, and notify QA. During the OOS investigation phase, risk assessment deepens through structured analysis, including laboratory checks and full-scale reviews, to identify root causes and evaluate their impact on manufacturing and product quality. Finally, at OOS closure, a comprehensive risk evaluation is documented, corrective and preventive actions are verified, and systemic trends are analyzed to ensure long-term compliance and continuous improvement. During the OOS investigation, the Step‑by‑Step Risk Assessment Process must be performed in sequence to ensure compliance and patient safety. Risk assessment for OOS results begins with an initial laboratory investigation, where the analyst’s performance, instrument calibration, sample preparation, and raw data are verified to rule out human or equipment error. If no laboratory error is confirmed, a full-scale investigation follows, reviewing batch records, retesting or resampling, and assessing the impact on manufacturing processes. During this stage, risk identification is performed to determine potential threats to patient safety, product quality, or compliance. Next, risk analysis is carried out using structured tools such as FMEA, fishbone diagrams, or fault tree analysis to quantify and understand the risks. Once analyzed, risk evaluation compares findings against acceptance criteria to decide whether the OOS is due to an assignable cause or represents a true product failure. Based on this, risk control measures are implemented, including corrective and preventive actions, SOP revisions, staff retraining, or method improvements. Throughout the process, risk communication ensures transparency, with findings documented and shared with QA or regulatory authorities when required. Finally, risk review is conducted to evaluate residual risks, confirm CAPA effectiveness, and trend OOS data for systemic issues, ensuring continuous improvement and regulatory compliance. Regards Jitendra Pund